Myovant Sciences Ltd. (MYOV) Receives Consensus Recommendation of “Buy” from Analysts

Myovant Sciences Ltd. (NYSE:MYOV) has earned an average rating of “Buy” from the seven ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $20.00.

A number of analysts have weighed in on MYOV shares. Evercore ISI started coverage on shares of Myovant Sciences in a report on Wednesday, August 16th. They set an “outperform” rating on the stock. Zacks Investment Research raised shares of Myovant Sciences from a “sell” rating to a “hold” rating in a report on Friday, August 25th. Cowen and Company reissued a “buy” rating on shares of Myovant Sciences in a report on Tuesday, October 3rd. Robert W. Baird reissued a “buy” rating and set a $20.00 price objective on shares of Myovant Sciences in a report on Wednesday, October 4th. Finally, JMP Securities reissued an “outperform” rating and set a $25.00 price objective (up previously from $23.00) on shares of Myovant Sciences in a report on Wednesday, October 4th.

Institutional investors and hedge funds have recently made changes to their positions in the company. Quantitative Systematic Strategies LLC purchased a new position in shares of Myovant Sciences during the second quarter worth approximately $165,000. Goldman Sachs Group Inc. purchased a new position in shares of Myovant Sciences during the second quarter worth approximately $174,000. Wells Fargo & Company MN grew its position in shares of Myovant Sciences by 331.9% during the first quarter. Wells Fargo & Company MN now owns 16,527 shares of the company’s stock worth $194,000 after acquiring an additional 12,700 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Myovant Sciences by 36.3% during the first quarter. Bank of New York Mellon Corp now owns 23,784 shares of the company’s stock worth $279,000 after acquiring an additional 6,330 shares during the last quarter. Finally, Swiss National Bank purchased a new position in shares of Myovant Sciences during the second quarter worth approximately $294,000. Institutional investors and hedge funds own 79.84% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Myovant Sciences Ltd. (MYOV) Receives Consensus Recommendation of “Buy” from Analysts” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2017/11/20/myovant-sciences-ltd-myov-receives-consensus-recommendation-of-buy-from-analysts.html.

Myovant Sciences (NYSE MYOV) traded down $0.43 during mid-day trading on Monday, reaching $12.96. 24,600 shares of the company’s stock were exchanged, compared to its average volume of 56,896. Myovant Sciences has a 12 month low of $9.92 and a 12 month high of $18.85.

Myovant Sciences Company Profile

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Analyst Recommendations for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply